Boston Scientific is ‘very bullish’ on 2025 despite $200M tariff hit

The company joins Johnson & Johnson and Abbott as top medtech firms that expect an impact in the hundreds of millions of dollars from President Donald Trump’s tariff policies.

By Ricky Zipp • April 23, 2025

Intuitive lowers profit margin forecast due to tariff pressure

CFO Jamie Samath cautioned that the trade environment, financial pressures on hospitals and macroeconomic risks could extend timelines for robot purchases.

By Susan Kelly • April 23, 2025

Intuitive, Boston Scientific and Edwards next up in medtech earnings

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and competitive dynamics in key markets.

By Nick Paul Taylor • April 21, 2025

J&J’s electrophysiology sales dip amid slow Varipulse start

Johnson & Johnson’s electrophysiology unit struggled in the first quarter, as the company chases Medtronic and Boston Scientific in the red-hot pulsed field ablation market.

By Ricky Zipp • April 16, 2025

Abbott expects a ‘few hundred million’ in tariff costs in 2025

CEO Robert Ford told investors the company had considered raising its earnings forecast for 2025, but decided to maintain it in light of the new tariffs.

By Elise Reuter • April 16, 2025

J&J expects tariff charge of $400M this year

CFO Joe Wolk, who revealed the figure Tuesday morning on CNBC, told investors the charge was primarily in the healthcare giant’s medtech business.

By Ricky Zipp • April 15, 2025

Pharma bosses face down investor angst on tariffs, HHS chaos

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S. tariffs on their products.

By Ned Pagliarulo • April 14, 2025

Tariffs top of mind for medtech firms this earnings season

GE Healthcare and Medtronic said they are preparing mitigation plans as they assess the potential ramifications of Trump’s tariff policies.

By Susan Kelly • April 14, 2025

Newly public Beta Bionics reports sales surge; Dexcom hires CCO

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.

By Nick Paul Taylor • March 28, 2025

Hinge Health, a virtual physical therapy firm, files for IPO

The digital health IPO market has slowed to a crawl in recent years, but experts say it could be poised for a turnaround in 2025.

By Emily Olsen • March 13, 2025

Elekta CEO Gustaf Salford to leave after board sees need for new leader

Laurent Leksell, Elekta’s chairman of the board, said the company needs “new leadership that can further intensify the focus on improving profitability and strengthen growth.”

By Nick Paul Taylor • Feb. 27, 2025

After tough year, Baxter looks for next CEO to drive growth

Interim CEO Brent Shafer said the medical products maker is ready to begin a new era after several years of “heavy lifting” to simplify the business structure.

By Susan Kelly • Feb. 21, 2025

Philips expects sales struggles in China to continue in 2025

Philips forecast a double-digit sales decline in China for the first half of 2025 after reporting “significant deterioration” of demand in October.

By Nick Paul Taylor • Feb. 19, 2025

Medtronic nears FDA submission for Hugo robot

CEO Geoff Martha said Medtronic would submit its application for urological procedures to the Food and Drug Administration by the end of March.

By Ricky Zipp • Feb. 18, 2025

Edwards predicts second-half lift from TAVR label expansion

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

By Susan Kelly • Feb. 12, 2025

Inspire Medical reveals DOJ civil investigation

CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January for information on marketing and reimbursement practices.

By Ricky Zipp • Feb. 11, 2025

Mass General Brigham to conduct largest layoffs in its history

MGB said the layoffs were necessary to get ahead of an anticipated budget shortfall of $250 million over the next two years.

By Susanna Vogel • Feb. 11, 2025

M&A and a separation take center stage in latest earnings season

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 billion buy of Paragon 28.

By Susan Kelly • Feb. 10, 2025

Zimmer touts ASC opportunity with Paragon 28 purchase

With the $1.1 billion acquisition, Zimmer Biomet expects its sports medicine, extremities and trauma segment will outpace hips and knees.

By Elise Reuter • Feb. 6, 2025

Boston Scientific closes its year of PFA on a high note

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth quarter for the company’s electrophysiology group.

By Ricky Zipp • Feb. 5, 2025

23andMe considers sale as cash runs low

The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its operations and financial commitments.

By Nick Paul Taylor • Jan. 30, 2025

Getinge exits surgical perfusion, creating opportunity for Livanova

Getinge CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced the company off the U.S. market in 2015.

By Nick Paul Taylor • Jan. 30, 2025

Stryker to sell spinal implants business

The company named a new CFO and shared an update on its planned Inari Medical acquisition.

By Elise Reuter • Jan. 29, 2025

Intuitive execs cast wary eye on potential Trump tariffs

The surgical robot leader is watching developments under the new administration but has not included any tariff impact in its financial forecast.

By Susan Kelly • Jan. 24, 2025

Abbott expects to launch first PFA device outside of the US this year

CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.

By Elise Reuter • Jan. 22, 2025